

AQILION

Helsingborg November 30, 2023

Press release

Aqilion appoints Gustaf Albèrt as new CFO

AQILION (publ) has appointed Gustaf Albèrt as the new CFO. Gustaf has solid financial experience from both smaller and larger listed groups and has worked as CFO in a listed environment within the life science industry. As CFO, he will be part of the Group management and report to the CEO.

In connection with the recruitment of Gustaf Albèrt, Torgeir Vaage, former VP and CFO, is leaving Aqilion.

"It is very pleasing and strategically important that we have appointed Gustaf as the new CFO. He will bring broad and relevant experience and expertise to enhance the Aqilion's finance function and contribute to the company's future financing. At the same time, I would like to take the opportunity to thank Torgeir Vaage for his contributions to the company over many years", says Sarah Fredriksson, CEO of Aqilion.

For more information, please contact:

Sarah Fredriksson, CEO, AQILION AB, + 46 (0)70 261 4575, sarah.fredriksson@aqilion.com

About Aqilion

Aqilion is a Swedish biotech company that develops innovative new therapies for diseases caused by chronic inflammation and dysfunctional immune reactions.

The company is mainly active in the idea stage to early clinical development. The goal is to demonstrate the clinical and commercial potential of the medical innovation to attract industrial partners and buyers, who in turn have the capacity to continue clinical development and take the drug to the patients.

Aqilion runs its development programs in a partly virtual organization in close collaboration with selected partners with specific expertise in drug development.

AQILION AB (publ) is a Swedish public limited company headquartered in Helsingborg, www.aqilion.com